Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma.
Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma. Expert Rev Mol Diagn. 2016 07; 16(7):737-49.